Clinical Edge Journal Scan

Smoking worsens disease outcomes in RA


 

Key clinical point: Smoking worsened disease activity and health-related quality of life at 1 year in patients with rheumatoid arthritis (RA), with effects being persistent at 3 years and early smoking cessation vs. continued smoking being associated with improved disease activity.

Major finding: At 1 year, current smokers vs. non-smokers were at a higher risk for a swollen joint number above the median (odds ratio [OR] 1.7; P = .001) and 36-Item Short-Form Health Survey physical (OR 1.5; P = .006) and mental (OR 1.4; P = .03) scores below the median, with effects being persistent at 3 years. Patients who stopped vs. continued smoking within 1 year reported a lower swollen joint number (P = .002).

Study details: Findings are from a population-based case-control study including 1531 patients with newly diagnosed RA who were followed-up for 3 years, of which 376 patients were current smokers.

Disclosures: This study was supported by grants from the Swedish Medical Research Council and other sources. The authors declared no conflicts of interest.

Source: Alfredsson L et al. Influence of smoking on disease activity and quality of life in patients with rheumatoid arthritis: Results from a Swedish case-control study with longitudinal follow-up. Arthritis Care Res (Hoboken). 2022 (Sep 23). Doi: 10.1002/acr.25026

Recommended Reading

Evusheld PrEP may protect immunocompromised patients from severe COVID-19
MDedge Rheumatology
Previous endemic coronavirus encounters linked with long COVID
MDedge Rheumatology
Hard-rock mining and other mining work raise RA risk
MDedge Rheumatology
JAK inhibitors show no excess cardiovascular safety signal in French nationwide cohort
MDedge Rheumatology
Ten-day methotrexate pause after COVID vaccine booster enhances immunity against Omicron variant
MDedge Rheumatology
Increased risk for severe COVID-19 in rheumatoid arthritis and its phenotypic subgroups
MDedge Rheumatology
RA in remission: Subclinical inflammation lower with cs/bDMARDs combination vs. monotherapy
MDedge Rheumatology
Withdrawing methotrexate increased disease activity without affecting remission rates in RA patients at target
MDedge Rheumatology
RA: Increased risk for VTE with JAK inhibitors
MDedge Rheumatology
Suboptimal early RA management predicts difficult-to-treat RA
MDedge Rheumatology